Skip to main content
Equibles

NRSN · NeuroSense Therapeutics Ltd.

Track NRSN — free

Use NRSN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NRSN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.67 -0.41 (-13.19%) At close · Oct 19
Rebalance outlook locked
Market Cap
$5.82M
Shares
1.90M
Volume · Oct 19 117.61K Avg daily vol (25 sessions) 26.33K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.67 Open$2.94 Day$2.36–2.94 52W close$2.67–25.00 Avg vol 30d33K Short int27K · 1.4% float · 1.2d Short vol29% DataDec 2021–Oct 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$9.98M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-97.3%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+37.0%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
1.4%
Latest settlement · 1.2 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 18.4 · elevated Equity put/call 0.55
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −80%
below
Price vs 50-day avg −60%
below
RSI (14) 23
oversold
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −60%
trailing
6-month return −82%
trailing
YTD return −83%
this year
Relative strength −90%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $7 › 200d $14 — 200d above 50d
Institutional flow Distributing
-7% holders QoQ · +2 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
1.42% of float · ▼ -29.7% MoM · 1.2 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Steady
14 holders — mid 3-yr range
Squeeze score 33
low risk · 0–100
Fundamentals
Strong
EPS growth +19%
Y/Y
Free cash flow $-7.7M
Balance sheet $166.0K
net cash
Quant / Vol
risk profile
Very High
Volatility 92%
annualized · 1-yr
Max drawdown −89%
past year
ATR 25.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−80% Bearish
Price vs 50-day avg
−60% Bearish
RSI (14)
23 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $7 › 200d $14 — 200d above 50d
Institutional flow Distributing
-7% holders QoQ · +2 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
1.42% of float · ▼ -29.7% MoM · 1.2 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Steady
14 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $3 Now $3 · 0% Range high $25
vs 200-day avg -80% vs 50-day avg -60%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
NRSN
NeuroSense Therapeutics Ltd.
this stock
$5.82M — — — 1.4%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $127.73B +10.7% +46.2% 29.4 1.8%
MRNA
Moderna, Inc.
 $87.04B +669.4% +4.3% — 7.7%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.41B +1.3% +20.8% 19.6 2.1%
CSLLY
Csl Ltd
 $64.50B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
14
% held
9.7%
Net QoQ
+595 sh
Top holder
UBS Group AG
Held Float
View
Short & Settlement
Short Interest Falling
Shares short
26.9K
Days to cover
1.2d
Change
-11.4K sh
View
Short Volume
Short vol %
29%
As of
Oct 19, 2026
Short Total
View
Fails to Deliver
FTD shares
1
Value
$5
As of
Sep 30, 2026
View
Off-Exchange
Off-exchange %
63.5%
Week of
Sep 14, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-11.1M
EPS diluted
$-8.80
View
Filings
SEC Filings
Latest
6-K
Filed
Oct 19, 2026
This year
31

NeuroSense Therapeutics filed a U.S. patent application covering PrimeC's use for traumatic brain injury, including concussion, blast-related injury and CTE. If granted, the patent is expected to provide protection through 2047.

View
Exempt Offerings
Offering
$5.0M
Filed
Dec 12, 2024
View

Performance

5D 20D 120D MTD YTD
NRSN -23.4% -59.7% -82.3% -39.8% -82.7%
SPY -1.5% -0.9% +7.7% +0.5% +12.4%
vs SPY -21.9% -58.8% -90.0% -40.3% -95.1%
Key facts CIK 1875091 CUSIP M74240207 Visit website Investor relations